Drager sales up 3.7%:
This article was originally published in Clinica
Medtech revenues contributed some 65% of German company Drager's total sales of DM 1,435 million ($1,000 million) in 1995, which were up 3.7% on the previous year. When expressed in local currencies this represents growth of 8%. Medical technology sales increased around 4% in Germany and about 13% abroad. Group net profits were DM 13.7 million, down nearly 10% on 1994. The company blames high German production costs and currency effects. The company spent DM 106 million on R&D, compared with DM 93.5 million in 1994. Drager TGM, which will expand the company's equipment servicing programme for hospitals, was set up in Kirchheimbolanden, Germany, at the end of May.
You may also be interested in...
ConMed's CFO Todd Garner told delegates at the Jefferies Healthcare conference that the company's orthopedic franchise is focused on its pipeline and meeting customer's needs. See what the CFO said about it here.
Formal dispute resolution was key element in four-month turnaround from rejection by US FDA to approval for golodirsen, the second Sarepta DMD drug to clear the agency after appearing to have minimal prospects.
Correvio’s attempt to move vernakalant from 'clinical hold' to 'FDA approved' was a huge long shot. But the advisory committee vote – and looming FDA rejection – are another indication that real-world data is not a panacea.